Manage your formulary budget
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide|
|Abstract:||The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.|
|Inventor(s):||D'Amato; Robert (Lancaster, PA)|
|Assignee:||Celgene Corporation (Summit, NJ)|
Patent Claim Types:|
see list of patent claims
|Use; Dosage form;|
Back Citations: 29th percentile
Forward Citations: 0th percentile
|Patent Number||Expiration Date|
|7,723,361||May 25, 2014|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||218865||<disabled in preview>|
|Austria||304356||<disabled in preview>|
|Australia||676722||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.